VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has taken another step in the development of its proprietary BiTAC(R)-TCE platform after receiving Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI), providing regulatory feedback on the biological rationale and proposed non-clinical development strategy for its lead therapeutic program. The announcement, released on July 20, signals progress as the biotechnology company prepares its most advanced BiTAC(R)-TCE candidate for future clinical development (https://ibn.fm/zBiDU).
The regulatory feedback provides early guidance on the company's biological rationale, safety assessments, and non-clinical development plan for its novel therapeutic platform. VERAXA believes the advice helps reduce development uncertainty by providing greater clarity before advancing toward clinical studies. Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, helping companies align their development strategies with regulatory expectations regarding safety, tolerability, and efficacy.
The company's lead BiTAC(R)-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These include factors set forth under "Risk Factors" in the Company's SEC filings, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA.
